Glycostem Therapeutics B.V.

1:00 PM - 1:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
Glycostem is focused on the development of first and second generation stem cell-derived Natural Killer cells (NK cells) as a therapeutic asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells. NK cells play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM). When the cells of a patient’s immune system are not strong enough to fight cancer cells, the infusion of NK cells collected from a donor may contribute to a better response by the patient's immune system.

Thanks to its eight patent families, longstanding technical expertise and resources, as well as Orphan Drug Designation, Glycostem has secured a leadership position in the global NK cell market.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Non-modified NK cells
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Glycostem Therapeutics